ABOS / Acumen Pharmaceuticals, Inc. (ABOS) CEO Daniel O'Connell on Q1 2022 Results - Earnings Call Transcript

Acumen Pharmaceuticals' ACU193 shows promise as a potential treatment for early-stage Alzheimer's Disease, targeting amyloid beta oligomers with a mor more_horizontal

Acumen Pharmaceuticals is developing a monoclonal antibody, ACU193, that targets Amyloid beta oligomers (AβOs) in Alzheimer's disease. AβOs are smal more_horizontal

CHARLOTTESVILLE, Va. and CARMEL, Ind., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceuti more_horizontal

Here is how Acumen Pharmaceuticals, Inc. (ABOS) and Haemonetics (HAE) have performed compared to their sector so far this year. more_horizontal

Two years removed from an IPO, Acumen Pharmaceuticals, Inc. NASDAQ: ABOS looks like it made a good decision to go public. Shares of the Charlottesvill more_horizontal

Acumen's shares rose more than 54% on Monday on positive trial news. Investors were likely taking profits Tuesday. more_horizontal

Positive topline results released from phase 1 INTERCEPT-AD study, which used ACU193 for the treatment of patients with early AD. The global market fo more_horizontal

Acumen Pharmaceuticals (NASDAQ: ABOS ) stock is on the rise Monday after the company released data from a Phase 1 clinical trial. This data comes fro more_horizontal